SIBP04 + paclitaxel + carboplatin

SIBP04 + paclitaxel + carboplatin is a combination drug regimen comprising **SIBP04** (a biosimilar of bevacizumab), **paclitaxel** (a taxane antineoplastic agent), and **carboplatin** (a platinum-based chemotherapeutic agent). This combination is used as first-line therapy for locally advanced or metastatic non-squamous non-small-cell lung cancer (nsqNSCLC). - **SIBP04** acts by binding vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis essential for tumor growth. - **Paclitaxel** promotes microtubule stabilization and prevents cell division. - **Carboplatin** causes DNA crosslinking, leading to apoptosis of rapidly dividing cells. Clinical studies show this combination regimen is comparable in efficacy and safety to bevacizumab (Avastin) plus paclitaxel and carboplatin, with an objective response rate of 55-62% depending on patient subset and significant benefit in populations including those with EGFR mutations[1][3]. SIBP04 is generally administered intravenously along with paclitaxel and carboplatin in 3-week cycles for up to six cycles, followed by maintenance SIBP04 in patients without progression[1][3].

Brand names

Avastin (reference for bevacizumab)Taxol (reference for paclitaxel)

Other names

bevacizumab biosimilar SIBP04 + paclitaxel + carboplatin